89Zr-ss-pertuzumab PET/CT for Breast Cancer

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, NY
Breast Cancer+2 More Conditions89Zr-ss-pertuzumab PET/CT - CombinationProduct
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new cancer drug is safe for people with HER2+ cancer.

Eligible Conditions
  • HER2-positive Breast Cancer
  • HER2 Positive Metastatic Breast Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Up to 20 months

Up to 20 months
Evaluate clinical safety of 89Zr-ss-pertuzumab

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

3 Treatment Groups

Arm A
1 of 3
Arm B
1 of 3
89Zr-ss-pertuzumab administration
1 of 3

Experimental Treatment

20 Total Participants · 3 Treatment Groups

Primary Treatment: 89Zr-ss-pertuzumab PET/CT · No Placebo Group · Phase 1

Arm AExperimental Group · 3 Interventions: 89Zr-ss-pertuzumab PET/CT, Static PET/CT scans, 89Zr-pertuzumab PET/CT · Intervention Types: CombinationProduct, DiagnosticTest, CombinationProduct
Arm BExperimental Group · 3 Interventions: 89Zr-ss-pertuzumab PET/CT, Static PET/CT scans, 89Zr-pertuzumab PET/CT · Intervention Types: CombinationProduct, DiagnosticTest, CombinationProduct
89Zr-ss-pertuzumab administration
CombinationProduct
Experimental Group · 1 Intervention: 89Zr-ss-pertuzumab PET/CT · Intervention Types: CombinationProduct

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 20 months

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,861 Previous Clinical Trials
591,423 Total Patients Enrolled
195 Trials studying Breast Cancer
94,118 Patients Enrolled for Breast Cancer
National Institutes of Health (NIH)NIH
2,550 Previous Clinical Trials
24,611,125 Total Patients Enrolled
48 Trials studying Breast Cancer
108,838 Patients Enrolled for Breast Cancer
Randy Yeh, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
54 Total Patients Enrolled
1 Trials studying Breast Cancer
54 Patients Enrolled for Breast Cancer

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

To what extent is the population involved in this research endeavor?

"Affirmative, according to clinicaltrials.gov the trial is actively recruiting participants who were initially posted on November 30th 2020 and last edited September 13th 2022. At this time, 20 individuals are being recruited from two distinct sites." - Anonymous Online Contributor

Unverified Answer

Has the FDA given authorization for 89Zr-ss-pertuzumab PET/CT imaging?

"Taking into account the limited amount of safety and efficacy data, our team at Power have assigned 89Zr-ss-pertuzumab PET/CT a score of 1 on their scale from 1 to 3." - Anonymous Online Contributor

Unverified Answer

Has recruitment for this medical trial commenced?

"According to the records found on clinicaltrials.gov, enrollment for this medical research is ongoing. It was initially posted in November of 2020 and its details were most recently edited in September 2022." - Anonymous Online Contributor

Unverified Answer

Is this a pioneering endeavor in its field?

"According to current information, there are 90 active studies involving 89Zr-ss-pertuzumab PET/CT across 1397 cities and 62 countries. This medical technology was first tested in 2008 when Hoffmann La Roche sponsored a Phase 2 trial that included 720 patients. Over the last 12 years, 69 different trials utilizing this method have been concluded." - Anonymous Online Contributor

Unverified Answer

What previous experiments have included 89Zr-ss-pertuzumab PET/CT as one of their tools?

"The first study of 89Zr-ss-pertuzumab PET/CT occured in 2008 at SCRI Tennessee Oncology Chattanooga. Over the last 12 years, 69 trials have been concluded with 90 still underway; particularly, many are located around Newport Beach, California." - Anonymous Online Contributor

Unverified Answer

To what maladies is 89Zr-ss-pertuzumab PET/CT commonly prescribed?

"89Zr-ss-pertuzumab PET/CT is usually employed to treat the therapeutic procedure in question, but can also provide relief from brca1 gene, inflammatory breast cancer (ibc), and malignant neoplasms." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.